These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 24888813)
1. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Potter DM; Connelly AK; Dibridge SA; Whiteside TL; Okada H J Clin Oncol; 2014 Jul; 32(19):2050-8. PubMed ID: 24888813 [TBL] [Abstract][Full Text] [Related]
2. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745 [TBL] [Abstract][Full Text] [Related]
3. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H J Neurooncol; 2016 Dec; 130(3):517-527. PubMed ID: 27624914 [TBL] [Abstract][Full Text] [Related]
4. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657 [TBL] [Abstract][Full Text] [Related]
5. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Okada H; Butterfield LH; Hamilton RL; Hoji A; Sakaki M; Ahn BJ; Kohanbash G; Drappatz J; Engh J; Amankulor N; Lively MO; Chan MD; Salazar AM; Shaw EG; Potter DM; Lieberman FS Clin Cancer Res; 2015 Jan; 21(2):286-94. PubMed ID: 25424847 [TBL] [Abstract][Full Text] [Related]
6. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Fenstermaker RA; Ciesielski MJ; Qiu J; Yang N; Frank CL; Lee KP; Mechtler LR; Belal A; Ahluwalia MS; Hutson AD Cancer Immunol Immunother; 2016 Nov; 65(11):1339-1352. PubMed ID: 27576783 [TBL] [Abstract][Full Text] [Related]
7. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916 [TBL] [Abstract][Full Text] [Related]
8. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. Okada H; Low KL; Kohanbash G; McDonald HA; Hamilton RL; Pollack IF J Neurooncol; 2008 Jul; 88(3):245-50. PubMed ID: 18324354 [TBL] [Abstract][Full Text] [Related]
9. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. Yeung JT; Hamilton RL; Okada H; Jakacki RI; Pollack IF J Neurooncol; 2013 Jan; 111(2):103-11. PubMed ID: 23179498 [TBL] [Abstract][Full Text] [Related]
11. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961 [TBL] [Abstract][Full Text] [Related]
12. Brain tumor immunotherapy with type-1 polarizing strategies. Okada H Ann N Y Acad Sci; 2009 Sep; 1174():18-23. PubMed ID: 19769732 [TBL] [Abstract][Full Text] [Related]
13. Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma. Fenstermaker RA; Ciesielski MJ Expert Rev Vaccines; 2014 Mar; 13(3):377-85. PubMed ID: 24521310 [TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611 [TBL] [Abstract][Full Text] [Related]
15. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. Mehrotra S; Britten CD; Chin S; Garrett-Mayer E; Cloud CA; Li M; Scurti G; Salem ML; Nelson MH; Thomas MB; Paulos CM; Salazar AM; Nishimura MI; Rubinstein MP; Li Z; Cole DJ J Hematol Oncol; 2017 Apr; 10(1):82. PubMed ID: 28388966 [TBL] [Abstract][Full Text] [Related]
16. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764 [TBL] [Abstract][Full Text] [Related]
17. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. Okada H; Lieberman FS; Walter KA; Lunsford LD; Kondziolka DS; Bejjani GK; Hamilton RL; Torres-Trejo A; Kalinski P; Cai Q; Mabold JL; Edington HD; Butterfield LH; Whiteside TL; Potter DM; Schold SC; Pollack IF J Transl Med; 2007 Dec; 5():67. PubMed ID: 18093335 [TBL] [Abstract][Full Text] [Related]
18. Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. Müller S; Agnihotri S; Shoger KE; Myers MI; Smith N; Chaparala S; Villanueva CR; Chattopadhyay A; Lee AV; Butterfield LH; Diaz A; Okada H; Pollack IF; Kohanbash G JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618666 [TBL] [Abstract][Full Text] [Related]
19. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206 [TBL] [Abstract][Full Text] [Related]
20. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Iwami K; Shimato S; Ohno M; Okada H; Nakahara N; Sato Y; Yoshida J; Suzuki S; Nishikawa H; Shiku H; Natsume A; Wakabayashi T Cytotherapy; 2012 Jul; 14(6):733-42. PubMed ID: 22424217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]